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Summary The mutagenic and cytotoxic activity of two newly synthesized doxorubicin derivatives and of one
daunorubicin derivative were studied in V79 Chinese hamster cells and bacteria (Salmonella typhimurium and
Escherichia coli). The results showed that all the compounds tested were cytotoxic and mutagenic for both
prokaryotic and eukaryotic cells. However, in both systems, the two 4-desmethoxy- and the 4'-desoxy-
derivatives were more active than the parent compounds, indicating that modifications in the aglycone or in
the sugar moiety can produce appreciable changes in the biological properties of the anthracycline antibiotics.
The in vitro activities observed in this study correlated with the in vivo antitumour potency.
Doxorubicin and daunorubicin are effective agents
for the treatment of human malignant diseases
(Arcamone et al., 1969; Blum & Carter, 1974; Di
Marco et al., 1963). The mechanism of action of
these agents is generally considered to involve the
insertion of the planar ring system into DNA and
the consequent inhibition of the DNA replication
and transcription processes (Zunino et al., 1972;
Meriwether & Bachur, 1972; Theologides et al.,
1968). However, it has been shown (Sinha, 1980;
Konopa, 1983) that these agents may be activated
to reactive intermediates that can covalently react
with DNA. Moreover, several authors have
proposed other cellular sites as targets for the
biological action of anthracycline antibiotics
(Tritton & Yee, 1982; Duarte-Karim et al., 1976;
Scheulen et al., 1982). In any event, when searching
for more effective and/or less toxic anticancer
agents of this class, it should be kept in mind that
their interaction with DNA may result in a geno-
toxic effect and eventually in carcinogenesis. Studies
on the structure-activity relationships have
indicated that some structural features of these
antitumour antibiotics are important determinants
for their binding to DNA. It has been shown
(Arcamone et al., 1975; Zunino et al., 1972) that
modifications in the amino sugar moiety, as well as
in the aglycone moiety can change the ability of
these molecules to bind to DNA and eventually
their biological properties.
With the aim of elucidating the relationships
between the molecular structure and biological
properties of the anthracycline antibiotics, doxo-
rubicin, daunorubicin and their derivatives 4-
desmethoxydoxorubicin, 4-desmethoxydaunorubicin
and 4'-desoxydoxorubicin were compared for their
cytotoxic and mutagenic activity in two in vitro
biological systems, i.e., the bacterial systems
employing Escherichia coli K12 and Salmonella,
typhimurium Ames strains, and the mammalian cell
system V79/HGPRT.
Materials and methods
Chemicals
Doxorubicin, daunorubicin and the new derivatives
4-desmethoxydoxorubicin, 4'-desoxydoxorubicin and
4-desmethoxydaunorubicin were kindly provided
by Farmitalia-Carlo Erba. Their chemical structures
are shown in Figure 1.
Bacterial strains
The bacterial strains used were the following
(Bachmann, 1972; Ames et al., 1975):
E. coli K12:
AB1157 (thr-, leu-, pro-, his-, thi-, arg-)
AB1186 (same as AB1157 plus uvrA)
AB2463 (same as AB1157 plus recA)
AB2480 (thi-, pro-, recA, uvrA)
S. typhimurium LT2:
TA1535 (hisG46, uvrB, rfa)
TA1538 (hisD3052, uvrB, rfa)
TA100 (hisG46, uvrB, rfa, pKMJOJ)
TA98 (hisD3052, uvrB, rfa, pKMJOJ)
Mutagenesis assay
Mutagenicity was assayed according to the plate-
incorporation method of Ames et al. (1975), by
counting his + revertants. Each assay included the
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Figure 1 Chemical structure of: daunorubicin
(R1=H; R2=OH; R3=-OCH3); doxorubicin
(R10OH; R2=OH; R3=-OCH3); 4-desmethyoxy-
doxorubicin (R1=OH; R2=OH; R3=H); 4'-desoxy-
doxorubicin (R1=OH; R2=H; R3=-OCH3); 4-
desmethoxydaunorubicin (R1=H; R2=OH; R3=H).
appropriate controls. The number of induced
mutants was obtained by subtracting the number of
spontaneous revertant colonies.
The historical means of spontaneous revertants
were:
TA100: 107
TA98 : 24.5
TA1538: 18.2
TA1535: 16.8
Each datum point was the mean value from 3
experiments carried out in duplicate.
Antibacterial test
Antibacterial activity of the 5 compounds was
tested on E. coli K12 strains with different repair
capabilities. Fifty ul of the appropriate dilutions of
the compounds were plated into 8 mm wells cut
into agar plates containing bacteria. Davis-Mingioli
synthetic medium (Davis Mingioli, 1950) with
adequate cofactors was used. The plates were
placed overnight in a 37°C incubator and the
diameters of the growth inhibition zones were
measured.
Cell line cultures
The Chinese hamster cell line V79, clone G5
(selected in our laboratory for a high colony-
forming efficiency and a low level of spontaneous
mutants) was cultured in Dulbecco modified Eagle's
minimal essential medium with 10% foetal calf
serum (FCS, Lagitre), 100 IU ml - penicillin and
100Mgml- 1 streptomycin.
Treatment of V79 cells
For the acute treatment, 2 x 106 cells were plated in
50mm diameter Petri dishes (Corning) and
incubated for 24h prior to the treatment with the
anthracycline antibiotics. The cultures were then
washed and the medium was replaced by medium
without FCS but containing the drugs at various
concentrations, with or without 50% rat liver
homogenate fraction plus 10% cofactors. The rat
liver homogenate was prepared in our laboratory
according to the previously described technique
(Ames et al., 1975), but resuspended in Hank's
balanced saline solution plus 20mM HEPES
(HBSSH); cofactors were added at the following
final concentrations: NADPH 2.5mM; glucose-6-
phosphate 10mM; MgCl2 10mM. The cultures
were then incubated for 1 h at 370C in a humidified
5% CO2 atmosphere.
For the prolonged treatment, 5 x 105 cells were
plated in 50mm diameter Petri dishes and
incubated for 24h prior to the treatment. The
cultures (9-10 x 105 cells/Petri dish) were then
washed and the medium was replaced by medium
with FCS plus the anthracycline antibiotics. The
cultures were incubated for a further 24h, and the
medium containing the drugs was changed at 6h
intervals.
At the end of both acute and prolonged
treatment, all the cultures were washed x4 with
medium without FCS.
Assay of the mutagenic and cytotoxic activity of the
drugs
Cells were plated 200 per 50mm dish (4 replicates)
for the determination of the induced toxicity
(surviving fraction) and 2 x 105 cells per 100mm
dish (5 replicates) for the selection of mutants
according to the previously described technique
(Abbondandolo et al., 1976). One plate containing
7.5 x 105 cells was also made to propagate the
culture for the selection at the appropriate
expression time. We found that the optimum
expression time was 7 days after treatment.
Mutants defective in the hypoxanthine-guanine
phosphorybosyl-transferase were selected by adding
6-thioguanine 1 h after plating, at the final concen-
tration of 4,ugml-. Both survival and mutation
plates were stained with 1% methylene blue 7 days
after plating and colonies were scored macro-
scopically.
Results
The mutagenic activity of doxorubicin, dauno-
rubicin and their derivatives 4'-desoxydoxorubicin,
4-desmethoxydoxorubicin and 4-desmethoxydauno-GENOTOXICITY OF ANTHRACYCLINE ANTIBIOTICS
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Figure 2 Mutagenic activity of daunorubicin, doxorubicin and their derivatives on S. typhimurium strains.
Note the different ordinate scales. Points are the mean values from 3 independent experiments: the s.e. ranged
between 1 and 9.7%. Legend: A=doxorubicin; B=daunorubicin; C=4'-desoxydoxorubicin; D=4-
desmethoxydoxorubicin; E=4-desmethoxydaunorubicin.
rubicin was assayed on TA1535, TA1538 and
their derivatives TA100 and TA98 Salmonella
typhimurium strains. None of the compounds tested
induced any revertant on the TA1535 strain,
whereas they induced a significant number of
revertants on TA1538. The mutagenic response was
enhanced in the strains with the pKM101 plasmid,
where all the compounds were mutagenic; TA98
showed a higher sensitivity than TA100 (Figure 2).
The addition of S-9 mix for metabolic activation
did not modify the mutagenic response of either of
these strains (data not shown). The derivatives of
doxorubicin and daunorubicin were more active
than their respective parent compounds, except for
TA98, where 4-desmethoxydaunorubicin is as
mutagenic as daunorubicin.
The test of selective toxicity for DNA repair-
deficient E. coli K12 strains showed that none of
the anthracycline antibiotics has antibacterial
activity on the wild-type strain AB1157, whereas an
appreciable antibacterial activity was found on
AB2463 (recA) and on AB2480 (recAuvrA) strains
(data not shown).
On V79 Chinese hamster cells, doxorubicin and
daunorubicin were found to be weakly mutagenic,
whereas their derivatives showed a more marked
activity, although at doses that sharply reduced the
survival of the cells (Figure 3, lower part).
However, when the mutagenic activity of the drugs
is compared at equitoxic doses (e.g. 10% survival),
only the 4'desoxydoxorubicin induced a number of
mutants significantly higher than the other
compounds (Figure 4).
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Figure 3 The upper part of the figure shows the
cytotoxic, and the lower part the mutagenic activity of:
doxorubicin (A), daunorubicin (B), 4'desoxydoxo-
rubicin (C), 4-desmethoxydoxorubicin (D), and 4-
desmethoxydaunorubicin (E) on V79 Chinese hamster
cells. Points are the mean values from 3 or more
independent experiments: the s.e. ranged between 0.6
and 20%.
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Figure 4 The mutagenic activity (expressed as number
of 6-thioguanine-resistant clones 10-6 colony forming
cells) of doxorubicin, daunorubicin and their
derivatives, plotted against the surviving fraction. The
regression curves are shown, and vertical bars
represent the s.e. of the curves.
All the compounds were highly cytotoxic at doses
varying from 0.05-0.5pgml-'. 4-desmethoxydauno-
rubicin and 4-desmethoxydoxorubicin were the
most active, since they reduced the surviving
fraction by >90% at 0.25 gml-' (Figure 3, upper
part). These results were obtained when the V79
cells were treated with the drugs for 1 h at 37'C;
when the treatment was prolonged for 24h, the
mutagenic effect did not increase, whereas the cyto-
toxicity did dramatically. In fact, at doses from
0.001-0.005pgml-1, no mutagenic effect could be
found, and only at 0.005 pgml - I was a slight
increase in the number of 6-thioguanine-resistant
clones observed. In contrast, doses higher than
O.Olgml-1 for 24h resulted in death of all the
cells (data not shown).
Another interesting finding is that in the presence
of S-9 mix, both the mutagenic and cytotoxic
effects were suppressed (Table I). Although the
production of inactive metabolites is consistent with
this finding, the observation that the anthracycline
antibiotics, after metabolic activation, bind to
microsomal proteins is relevant to this point
(Scheulen et al., 1982).
Discussion
As already reported for doxorubicin and
daunorubicin (Seino et al., 1978; Au et al., 1981;
Umezawa et al., 1978; Benedict et al., 1977), all 5
compounds were highly mutagenic in the Ames test
even without S-9 mix. In contrast, on V79 Chinese
hamster cells the mutagenicity: cytotoxicity ratio
was low. It is therefore possible that the induced
toxicity on V79 cells results at least in part from
damage to cellular targets other than DNA.
Several mechanisms have been proposed to
explain the biological effects of the anthracycline
antibiotics. Intercalation into double helical DNA
and subsequent inhibition of DNA and/or RNA
synthesis have been thought to be the main
molecular effect of these compounds (Zunino et al.,
1972; Meriwether & Bachur, 1972; Theologides et
al., 1968). Additional interactions with other
Table I Surviving fraction and mutation frequency on V79 cells of
doxorubicin, daunorubicin and their derivatives with and without S-9
mix.
Survivingfraction in % Mutationfrequencyb
-S9 mix +S9 mix -S9 mix +S9 mix
Control 100 100 11.15 5.7
Dimethyl-
nitrosaminea 100 94 10.1 123.3
Doxorubicinc 38.8 92.86 36.9 8.8
Daunorubicinc 8.15 87.8 80.3 2.3
4'desoxy-
doxorubicinc 11.1 97.4 232 8.1
4-desmethoxy-
doxorubicinc 3.9 98 187 2.1
4-desmethoxy-
daunorubicinc 2.4 not tested 134 not tested
Numbers are the mean values from at least two experiments.
aDimethyl-nitrosamine 5mM was used as positive control for the
metabolic activation.
bMutation frequency =6-thioguanine-resistant clones 10 6 colony
forming cells.
cCells were treated with the drug at 0.25pgml- for 1 h.GENOTOXICITY OF ANTHRACYCLINE ANTIBIOTICS 95
cellular components have been observed, in
particular with the cell surface (Tritton & Yee,
1982; Duarte et al., 1976; Scheulen, 1982). In
addition, the anthracycline antibiotics can be
metabolized in living cells to chemical products able
to react with cellular macromolecules and can
participate in oxidation-reduction reactions
(Arcamone et al., 1969); Sihna (1980) has shown
that enzymatically activated doxorubicin and
daunorubicin alkylate DNA probably via the
formation of a quinone methide intermediate.
Moreover, Scheulen et al. (1982) have proposed
that the enzymatic activation of these substances
can lead to the formation of reactive intermediates
that covalently bind to cellular proteins.
In contrast, the mutagenic activity of these
substances in eukaryotic cells shown in this and
other studies (Suter et al., 1980; Marquardt et al.,
1976) indicates that anthracycline antibiotics
introduce lesions in DNA that lead to errors during
replication and/or repair. The nature of the damage
and the way in which the cells deal with it can be
inferred from data obtained in S. typhimurium with
and without pKM101 plasmid and on E. coli K12
strains with different repair capabilities. The
different responses of TA1535 and TA1538 to the
five compounds suggest that the intercalation of the
molecule into DNA is probably involved in the
mutagenicity of anthracycline antibiotics. This does
not exclude the possibility that other metabolic
products formed inside the cells may interact with
DNA, but only indicates that these compounds are
frameshift mutagens.
The data obtained on E. coli K12 derivatives
with different repair capabilities clearly show that
the compounds interact with bacterial DNA. The
higher toxicity exerted on the recA strain AB2463
suggests that a recA-dependent pathway is required
for repair of the lesion.
These observations also apply to the doxorubicin
and daunorubicin derivatives. However, it is evident
from the present data that the derivatives are more
cytotoxic and more mutagenic than the parent
compounds, both in prokaryotic and in eukaryotic
systems. These differences may be due to the
differences in the physicochemical properties as a
consequence of the modifications introduced in the
anthracycline aglycone or in the amino sugar moiety
(Di Marco et al., 1978a, b). These results are in
agreement with observations that the removal of
the methoxyl group at position 4 of the aglycone
causes a marked increase in cytotoxicity against
HeLa cells in vitro (Supino et al., 1977) and also an
increase in antitumour potency (Di Marco et al.,
1977, 1978b).
A slightly increased effectiveness has also been
reported with the 4'desoxy-derivative (Di Marco et
al., 1978a). These modifications may alter the
potency of the antracycline antibiotics in several
ways; in particular, the increased intracellular
accumulation may play a relevant role (Di Marco
et al., 1978a, b).
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